Oxytocin nasal spray trial to investigate social safety learning enhancement in social anxiety disorder
Background
Social Anxiety Disorder (SAD) is characterized by intense fear in social situations, significantly impacting quality of life. Current treatments often involve psychotherapy and medication, but efficacy can vary, and specific deficits in social learning persist. Oxytocin, a neuropeptide, is known to modulate fear responses and social interactions, making it a candidate for improving social cognition. This study aims to explore its potential to enhance social safety learning, a crucial aspect of overcoming social fears.
Study Design
This randomized, placebo-controlled clinical trial will enroll 120 participants, comprising adults with social anxiety disorder (SAD) and healthy volunteers. Participants will receive either oxytocin nasal spray or a placebo nasal spray. The study's primary objective is to compare the effects of oxytocin versus placebo on social safety learning, defined as learning safety through observing another individual's experience. All research activities will be conducted at the University of Washington.
Results
This study describes a research protocol, and no specific findings have been reported yet. The trial is currently underway to investigate whether oxytocin enhances social safety learning in adults with social anxiety disorder and healthy volunteers. Results will be reported upon completion of the study.
Key Findings
- Investigate if oxytocin enhances social safety learning in people with social anxiety disorder.
- Compare oxytocin effects to placebo in adults with SAD and healthy volunteers.
- Enroll approximately 120 participants at the University of Washington.
- Examine oxytocin's role as a chemical messenger in the brain for fear and social interactions.
- Assess learning safety through the experience of another individual.
Why It Matters
If oxytocin proves effective, it could represent a novel adjunctive therapy for social anxiety disorder (SAD), potentially improving the efficacy of existing treatments by targeting specific deficits in social learning. Enhancing social safety learning could help individuals with SAD generalize positive social experiences more effectively, reducing avoidance behaviors. This research could pave the way for optimized protocols combining oxytocin administration with behavioral therapies, offering a more robust and personalized approach to managing social fears. The use of a nasal spray suggests a potentially accessible and non-invasive delivery method for future clinical applications.
oxytocin
social anxiety disorder
social cognition
nasal spray
clinical trial
neuropeptide